Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.

Li LS, Reddy S, Lin ZH, Liu S, Park H, Chun SG, Bornmann WG, Thibodeaux J, Yan J, Chakrabarti G, Xie XJ, Sumer BD, Boothman DA, Yordy JS.

Mol Cancer Ther. 2016 Jul;15(7):1757-67. doi: 10.1158/1535-7163.MCT-15-0765. Epub 2016 Apr 12.

2.

Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.

Caruso JA, Campana R, Wei C, Su CH, Hanks AM, Bornmann WG, Keyomarsi K.

Cell Cycle. 2014;13(16):2587-99. doi: 10.4161/15384101.2015.942210.

3.

Synthesis of a Macrocycle Based on Linked Amino Acid Mimetics (LAAM).

Maxwell DS, Sun D, Peng Z, Martin DV, Bhanu Prasad BA, Bornmann WG.

Tetrahedron Lett. 2013 Oct 23;54(43):5799-5801.

4.

Asymmetric Synthesis of the C1-C6 Portion of the Psymberin Using an Evans Chiral Auxiliary.

Pal A, Peng Z, Schuber PT Jr, Bhanu Prasad BA, Bornmann WG.

Tetrahedron Lett. 2013 Oct 9;54(41):5555-5567.

5.

Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies.

Peng Z, Maxwell D, Sun D, Ying Y, Schuber PT Jr, Bhanu Prasad BA, Gelovani J, Yung WK, Bornmann WG.

Tetrahedron. 2014 Jan 28;70(4):984-990.

6.

Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.

Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, Morales JC, Motea EA, Bornmann WG, Yordy JS, Boothman DA.

Antioxid Redox Signal. 2014 Jul 10;21(2):237-50. doi: 10.1089/ars.2013.5462. Epub 2014 Apr 3.

7.

Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).

Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT Jr, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, Donato NJ, Bornmann WG.

Bioorg Med Chem. 2014 Feb 15;22(4):1450-8. doi: 10.1016/j.bmc.2013.12.048. Epub 2014 Jan 3.

8.

Curcumin glucuronides: assessing the proliferative activity against human cell lines.

Pal A, Sung B, Bhanu Prasad BA, Schuber PT Jr, Prasad S, Aggarwal BB, Bornmann WG.

Bioorg Med Chem. 2014 Jan 1;22(1):435-9. doi: 10.1016/j.bmc.2013.11.006. Epub 2013 Nov 12.

9.

Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level.

Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Pal A, Wang S, Balatoni J, Ghosh P, Lim ST, Volgin A, Shavrin A, Alauddin MM, Gelovani JG, Bornmann WG.

Bioorg Med Chem. 2014 Jan 1;22(1):623-32. doi: 10.1016/j.bmc.2013.10.040. Epub 2013 Nov 6.

10.

Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.

Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K.

PLoS One. 2013 Oct 16;8(10):e77262. doi: 10.1371/journal.pone.0077262. eCollection 2013.

11.

Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.

Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, Buchsbaum DJ, Spitz DR, Gao J, Boothman DA.

Mol Cancer Ther. 2013 Oct;12(10):2110-20. doi: 10.1158/1535-7163.MCT-12-0962. Epub 2013 Jul 24.

12.

Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase.

Sun D, Bhanu Prasad BA, Schuber PT Jr, Peng Z, Maxwell DS, Martin DV, Guo L, Han D, Kurihara H, Yang DJ, Gelovani JG, Powis G, Bornmann WG.

Bioorg Med Chem. 2013 Sep 1;21(17):5182-7. doi: 10.1016/j.bmc.2013.06.036. Epub 2013 Jun 27.

13.

RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B.

Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, Bornmann WG, Yu-Lee LY, Gallick GE, Zhang W, Lin SH, Kuang J.

Oncogene. 2014 May 1;33(18):2385-94. doi: 10.1038/onc.2013.182. Epub 2013 May 27.

14.

Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion.

Vanderslice P, Biediger RJ, Woodside DG, Brown WS, Khounlo S, Warier ND, Gundlach CW 4th, Caivano AR, Bornmann WG, Maxwell DS, McIntyre BW, Willerson JT, Dixon RA.

J Biol Chem. 2013 Jul 5;288(27):19414-28. doi: 10.1074/jbc.M113.479634. Epub 2013 May 23.

15.

Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy.

Arumugam T, Ramachandran V, Sun D, Peng Z, Pal A, Maxwell DS, Bornmann WG, Logsdon CD.

Mol Cancer Ther. 2013 May;12(5):654-62. doi: 10.1158/1535-7163.MCT-12-0771. Epub 2013 Jan 9.

16.

Binding partners for curcumin in human schwannoma cells: biologic implications.

Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R.

Bioorg Med Chem. 2013 Feb 15;21(4):932-9. doi: 10.1016/j.bmc.2012.12.008. Epub 2012 Dec 13.

PMID:
23294827
17.

A Practical Synthesis and X-ray Crystallographic Analysis of Dithymoquinone, a Photodimer of Thymoquinone.

Myers AL, Zhang YP, Kramer MA, Bornmann WG, Kaseb A, Yang P, Tran HT.

Lett Org Chem. 2012 Dec 1;9(10):762-766.

18.

A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.

Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ.

Cell Signal. 2011 Dec;23(12):2076-85. doi: 10.1016/j.cellsig.2011.08.002. Epub 2011 Aug 9.

PMID:
21855629
19.

Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.

Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr.

Cancer. 2011 Oct 1;117(19):4424-38. doi: 10.1002/cncr.26073.

20.

STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.

Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA.

Cancer Res. 2011 May 15;71(10):3658-68. doi: 10.1158/0008-5472.CAN-10-3647. Epub 2011 Mar 28.

21.

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.

Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ.

Blood. 2011 Mar 17;117(11):3151-62. doi: 10.1182/blood-2010-03-276477. Epub 2011 Jan 19.

PMID:
21248063
22.

Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.

Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA.

Clin Cancer Res. 2011 Jan 15;17(2):275-85. doi: 10.1158/1078-0432.CCR-10-1983. Epub 2011 Jan 11. Erratum in: Clin Cancer Res. 2011 Mar 1;17(5):1210-1.

23.

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.

PLoS One. 2010 Nov 29;5(11):e14124. doi: 10.1371/journal.pone.0014124.

24.

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ.

Cancer Res. 2010 Nov 15;70(22):9265-76. doi: 10.1158/0008-5472.CAN-10-1530. Epub 2010 Nov 2.

25.

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, Kessinger CW, Carnevale KA, Bornmann WG, Boothman DA, Gao J.

Cancer Res. 2010 May 15;70(10):3896-904. doi: 10.1158/0008-5472.CAN-09-3995. Epub 2010 May 11.

26.

ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.

Wu J, Meng F, Ying Y, Peng Z, Daniels L, Bornmann WG, Quintás-Cardama A, Roulston D, Talpaz M, Peterson LF, Donato NJ.

Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28. No abstract available.

27.

Demonstration of microtubule-like structures formed with (-)-rhazinilam from purified tubulin outside of cells and a simple tubulin-based assay for evaluation of analog activity.

Edler MC, Yang G, Katherine Jung M, Bai R, Bornmann WG, Hamel E.

Arch Biochem Biophys. 2009 Jul 15;487(2):98-104. doi: 10.1016/j.abb.2009.05.014. Epub 2009 Jun 2.

28.

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.

Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D.

Mol Cancer Ther. 2009 May;8(5):1157-68. doi: 10.1158/1535-7163.MCT-08-1008. Epub 2009 May 5.

29.

Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.

Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC.

Clin Cancer Res. 2009 May 15;15(10):3472-83. doi: 10.1158/1078-0432.CCR-08-2714. Epub 2009 May 5. Erratum in: Clin Cancer Res. 2015 Apr 1;21(7):1774-5.

30.

Molecular-genetic PET imaging using an HSV1-tk mutant reporter gene with enhanced specificity to acycloguanosine nucleoside analogs.

Najjar AM, Nishii R, Maxwell DS, Volgin A, Mukhopadhyay U, Bornmann WG, Tong W, Alauddin M, Gelovani JG.

J Nucl Med. 2009 Mar;50(3):409-16. doi: 10.2967/jnumed.108.058735. Epub 2009 Feb 17.

31.

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.

Dong Y, Chin SF, Blanco E, Bey EA, Kabbani W, Xie XJ, Bornmann WG, Boothman DA, Gao J.

Clin Cancer Res. 2009 Jan 1;15(1):131-9. doi: 10.1158/1078-0432.CCR-08-1691.

32.

Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method.

Sankaranarayanapillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, Bornmann WG, Soghomonyan S, Pal A, Ramirez MS, Webb D, Kaluarachchi K, Gelovani JG, Ronen SM.

Mol Imaging. 2008 Mar-Apr;7(2):92-100.

PMID:
18706291
33.

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.

Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT.

Mol Cancer Ther. 2008 Jul;7(7):1846-50. doi: 10.1158/1535-7163.MCT-08-0168.

34.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

35.

Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses.

Wagner MW, Li LS, Morales JC, Galindo CL, Garner HR, Bornmann WG, Boothman DA.

J Biol Chem. 2008 Aug 1;283(31):21382-93. doi: 10.1074/jbc.M709953200. Epub 2008 May 14.

36.

Mechanism of activation and inhibition of the HER4/ErbB4 kinase.

Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ.

Structure. 2008 Mar;16(3):460-7. doi: 10.1016/j.str.2007.12.016.

37.

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M.

Leukemia. 2008 Apr;22(4):808-18. doi: 10.1038/sj.leu.2405098. Epub 2008 Jan 17.

PMID:
18200035
38.

An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.

Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, Boothman DA.

Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11832-7. Epub 2007 Jul 3.

39.

Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.

Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M.

Cell Cycle. 2006 Dec;5(23):2778-86. Epub 2006 Dec 1.

PMID:
17172851
40.

Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.

Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS.

Clin Cancer Res. 2006 Aug 1;12(15):4590-7.

41.

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. Epub 2006 Jun 5.

42.

Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy.

Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM.

Mol Cancer Ther. 2006 May;5(5):1325-34.

43.

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW.

Proc Natl Acad Sci U S A. 2006 May 9;103(19):7444-9. Epub 2006 May 1.

44.

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3773-81.

45.

Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery?

O'Brian CA, Chu F, Bornmann WG, Maxwell DS.

Expert Rev Anticancer Ther. 2006 Feb;6(2):175-86. Review.

PMID:
16445370
46.

Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.

Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, Larson SM.

Nucl Med Biol. 2005 May;32(4):313-21.

PMID:
15878500
47.

Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization.

Spassova MK, Bornmann WG, Ragupathi G, Sukenick G, Livingston PO, Danishefsky SJ.

J Org Chem. 2005 Apr 29;70(9):3383-95.

PMID:
15844973
48.

Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.

Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, Misico RI, Arzac GM, Burton G, Bornmann WG, Sutton D, Gao J, Boothman DA.

Clin Cancer Res. 2005 Apr 15;11(8):3055-64.

49.

An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle.

Spees WM, Gade TP, Yang G, Tong WP, Bornmann WG, Gorlick R, Koutcher JA.

Clin Cancer Res. 2005 Feb 15;11(4):1454-61.

50.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

Supplemental Content

Loading ...
Support Center